OBJECTIVE: The aim of this study was to characterize the demographic, behavioural, clinical and immunogenetic determinants of HIV-1 superinfection in a high-risk cohort of MSM. DESIGN: A retrospective cohort study of prospectively followed MSM. METHODS: Ninety-eight MSM with acute or early HIV-1 monoinfection were followed for a median of 15.6 months. Demographic and human leukocyte antigen (HLA) genotype data were collected at enrolment. Sexual behaviour, clinical and the infection status (monoinfection or superinfection) data were recorded at each visit (at enrolment and thereafter at a median of 4.2-month intervals). HIV-1 superinfection risk was determined by Cox regression and Kaplan-Meier survival analysis. RESULTS: Ten individuals (10.2%) had superinfection during follow-up. Cox regression did not show significantly increased superinfection risk for individuals with an increased amount of condomless anal intercourse, lower CD4 T-cell count or higher viral load, but higher number of sexual contacts demonstrated a trend towards significance [hazard ratio, 4.74; 95% confidence interval (95% CI), 0.87-25.97; P = 0.073]. HLA-A*29 (hazard ratio, 4.10; 95% CI, 0.88-14.76; P = 0.069), HLA-B*35 (hazard ratio, 4.64; 95% CI, 1.33-18.17; P = 0.017), HLA-C*04 (hazard ratio, 5.30; 95% CI, 1.51-20.77; P = 0.010), HLA-C*16 (hazard ratio, 4.05; 95% CI, 0.87-14.62; P = 0.071), HLA-DRB1*07 (hazard ratio, 3.29; 95% CI, 0.94-12.90; P = 0.062) and HLA-DRB1*08 (hazard ratio, 15.37; 95% CI, 2.11-79.80; P = 0.011) were associated with an increased risk of superinfection at α = 0.10, whereas HLA-DRB1*11 was associated with decreased superinfection risk (hazard ratio, 0.13; 95% CI, 0.00-1.03; P = 0.054). CONCLUSION: HLA genes may, in part, elucidate the genetic basis of differential superinfection risk, and provide important information for the development of efficient prevention and treatment strategies of HIV-1 superinfection.
OBJECTIVE: The aim of this study was to characterize the demographic, behavioural, clinical and immunogenetic determinants of HIV-1 superinfection in a high-risk cohort of MSM. DESIGN: A retrospective cohort study of prospectively followed MSM. METHODS: Ninety-eight MSM with acute or early HIV-1 monoinfection were followed for a median of 15.6 months. Demographic and human leukocyte antigen (HLA) genotype data were collected at enrolment. Sexual behaviour, clinical and the infection status (monoinfection or superinfection) data were recorded at each visit (at enrolment and thereafter at a median of 4.2-month intervals). HIV-1 superinfection risk was determined by Cox regression and Kaplan-Meier survival analysis. RESULTS: Ten individuals (10.2%) had superinfection during follow-up. Cox regression did not show significantly increased superinfection risk for individuals with an increased amount of condomless anal intercourse, lower CD4 T-cell count or higher viral load, but higher number of sexual contacts demonstrated a trend towards significance [hazard ratio, 4.74; 95% confidence interval (95% CI), 0.87-25.97; P = 0.073]. HLA-A*29 (hazard ratio, 4.10; 95% CI, 0.88-14.76; P = 0.069), HLA-B*35 (hazard ratio, 4.64; 95% CI, 1.33-18.17; P = 0.017), HLA-C*04 (hazard ratio, 5.30; 95% CI, 1.51-20.77; P = 0.010), HLA-C*16 (hazard ratio, 4.05; 95% CI, 0.87-14.62; P = 0.071), HLA-DRB1*07 (hazard ratio, 3.29; 95% CI, 0.94-12.90; P = 0.062) and HLA-DRB1*08 (hazard ratio, 15.37; 95% CI, 2.11-79.80; P = 0.011) were associated with an increased risk of superinfection at α = 0.10, whereas HLA-DRB1*11 was associated with decreased superinfection risk (hazard ratio, 0.13; 95% CI, 0.00-1.03; P = 0.054). CONCLUSION:HLA genes may, in part, elucidate the genetic basis of differential superinfection risk, and provide important information for the development of efficient prevention and treatment strategies of HIV-1 superinfection.
Authors: H Hendel; S Caillat-Zucman; H Lebuanec; M Carrington; S O'Brien; J M Andrieu; F Schächter; D Zagury; J Rappaport; C Winkler; G W Nelson; J F Zagury Journal: J Immunol Date: 1999-06-01 Impact factor: 5.422
Authors: I P Keet; J Tang; M R Klein; S LeBlanc; C Enger; C Rivers; R J Apple; D Mann; J J Goedert; F Miedema; R A Kaslow Journal: J Infect Dis Date: 1999-08 Impact factor: 5.226
Authors: Aleksandr Lazaryan; Wei Song; Elena Lobashevsky; Jianming Tang; Sadeep Shrestha; Kui Zhang; Janet M McNicholl; Lytt I Gardner; Craig M Wilson; Robert S Klein; Anne Rompalo; Kenneth Mayer; Jack Sobel; Richard A Kaslow Journal: Hum Immunol Date: 2011-01-21 Impact factor: 2.850
Authors: Heather D Hickman; Angela D Luis; Wilfried Bardet; Rico Buchli; Casey L Battson; Michael H Shearer; Kenneth W Jackson; Ronald C Kennedy; William H Hildebrand Journal: J Immunol Date: 2003-07-01 Impact factor: 5.422
Authors: Keshet Ronen; Connor O McCoy; Frederick A Matsen; David F Boyd; Sandra Emery; Katherine Odem-Davis; Walter Jaoko; Kishor Mandaliya; R Scott McClelland; Barbra A Richardson; Julie Overbaugh Journal: PLoS Pathog Date: 2013-08-29 Impact factor: 6.823
Authors: Srinika Ranasinghe; Sam Cutler; Isaiah Davis; Richard Lu; Damien Z Soghoian; Ying Qi; John Sidney; Gregory Kranias; Michael D Flanders; Madelene Lindqvist; Bjorn Kuhl; Galit Alter; Steven G Deeks; Bruce D Walker; Xiaojiang Gao; Alessandro Sette; Mary Carrington; Hendrik Streeck Journal: Nat Med Date: 2013-06-23 Impact factor: 53.440
Authors: Daniel B Reeves; Amalia S Magaret; Alex L Greninger; Christine Johnston; Joshua T Schiffer Journal: J R Soc Interface Date: 2018-02 Impact factor: 4.118
Authors: Brian J Boyarsky; Mary Grace Bowring; Ashton A Shaffer; Dorry L Segev; Christine M Durand Journal: Curr Opin Organ Transplant Date: 2019-08 Impact factor: 2.640